ResearcherCatholic University of KoreaActive in the last 2 years
Se Jun Park
Matched on ORCID iD 0000-0001-5486-9818; OpenAlex author ID A5100693832. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 8
- Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm15207789↗
- Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implicatio… Last author DOI 10.3390/ijms262210908↗
- The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12040903↗
- Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12885-023-10811-8↗
- Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression. Co-author DOI 10.3390/jcm12165394↗
- Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a r… Co-author DOI 10.1186/s12885-021-08887-1↗
- Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. Co-author DOI 10.4251/wjgo.v13.i8.915↗
- Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.4251/wjgo.v11.i11.1021↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Myung Ah Lee · 8 shared papers, 2019–2026 · strength 1.68
- Paper Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.3390/jcm15207789↗
- Paper Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma wi… DOI 10.3390/ijms262210908↗
- Paper The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Ca… DOI 10.3390/biomedicines12040903↗
- Kabsoo Shin · 8 shared papers, 2019–2026 · strength 1.68
- Paper Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.3390/jcm15207789↗
- Paper Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma wi… DOI 10.3390/ijms262210908↗
- Paper The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Ca… DOI 10.3390/biomedicines12040903↗
- Tae Ho Hong · 7 shared papers, 2019–2026 · strength 1.52
- Paper Pretreatment Serum GDF-15 and Features of Clinical Vulnerability in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.3390/jcm15207789↗
- Paper Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma wi… DOI 10.3390/ijms262210908↗
- Paper The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Ca… DOI 10.3390/biomedicines12040903↗
- In-Ho Kim · 4 shared papers, 2021–2025 · strength 0.82
- Paper Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma wi… DOI 10.3390/ijms262210908↗
- Paper Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer. DOI 10.1186/s12885-023-10811-8↗
- Paper Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overex… DOI 10.3390/jcm12165394↗
- Ja Hee Suh · 2 shared papers, 2021–2023 · strength 0.36
- Paper Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overex… DOI 10.3390/jcm12165394↗
- Paper Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastat… DOI 10.1186/s12885-021-08887-1↗
- Ji Hyun Lee · 1 shared paper, 2026 · strength 0.33
- Dongwoo Cho · 1 shared paper, 2025 · strength 0.26
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.